2746 A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation von Shapira-Frommer, R, Oza, A, Domchek, S.M, Balmana, J, Patel, M.R, Chen, L.M, Drew, Y, Burris, H.A, Korach, J, Flynn, M, Bowering, V.L, Morgan, M.A, Watkins, S.P, Simpson, D, Goble, S, Maloney, L, Kristeleit, R

Volltext